172 results on '"Sandhu, Karamjeet"'
Search Results
2. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
3. Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation
4. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab
5. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract
6. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy
7. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
8. Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
9. Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
10. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia.
11. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.
12. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia.
13. Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer.
14. High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
15. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation
16. Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101
17. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
18. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
19. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia
20. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
21. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center
22. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
23. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents
24. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis
25. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations
26. AML-491 Real World Practice of FLAG-Idarubicin-Venetoclax in Relapsed Refractory AML: A Single Center Experience
27. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
28. A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.
29. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
30. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia
31. WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
32. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies
33. ALL-502 Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study
34. Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study
35. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions.
36. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
37. Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
38. Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
39. Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
40. Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
41. Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
42. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
43. Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience
44. Phase 1 Trial Investigating the Safety and Tolerability of Leflunomide in Patients with Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
45. Quality of Life in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Obecabtagene Autoleucel (obe-cel) in the Pivotal Phase 2 Felix Study
46. Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
47. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
48. AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage
49. POSTER: AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage
50. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.